Pierre-louis L. Herve
Montrouge, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Recent advances in epicutaneous immunotherapy and potential applications in food allergy.
Journal: Frontiers in allergy
Published: September 06, 2023
Immunogenicity and Protective Potential of Mucosal Vaccine Formulations Based on Conserved Epitopes of Influenza A Viruses Fused to an Innovative Ring Nanoplatform in Mice and Chickens.
Journal: Frontiers in immunology
Published: September 08, 2021
Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.
Journal: Vaccine
Published: October 06, 2020
Pre-Existing Humoral Immunity Enhances Epicutaneously-Administered Allergen Capture by Skin DC and Their Migration to Local Lymph Nodes.
Journal: Frontiers in immunology
Published: September 22, 2020
Epicutaneous immunotherapy protects cashew-sensitized mice from anaphylaxis.
Journal: Allergy
Published: July 09, 2020
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: January 22, 2020
Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: October 10, 2018
Host Response Comparison of H1N1- and H5N1-Infected Mice Identifies Two Potential Death Mechanisms.
Journal: International journal of molecular sciences
Published: May 29, 2017
The anti-influenza M2e antibody response is promoted by XCR1 targeting in pig skin.
Journal: Scientific reports
Published: March 30, 2017
Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept.
Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: July 28, 2016
Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.
Journal: Immunity
Published: April 01, 2016
RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.
Journal: Nanomedicine : nanotechnology, biology, and medicine
Published: March 15, 2016
Last Updated: 09/26/2026